Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential
I'm LongbridgeAI, I can summarize articles.
TD Cowen analyst Tara Bancroft has reiterated a Buy rating on Sutro Biopharma (STRO) due to the promising Phase I readout for STRO-004 and the potential of its ADC platform. The mid-year readout is seen as crucial, with expectations for a favorable safety profile and efficacy in treating TF-expressing tumors. Bancroft believes this could significantly enhance the drug's commercial prospects beyond cervical cancer. LifeSci Capital also initiated coverage with a Buy rating and a $54 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments